Author: Jessica.F

COA of Formula: C14H21Br2ClN2In 2016, Li, Wendong;Wang, Chenggang;Wu, Kechun;Liu, Haitao;Wang, Junqiu published 《Comparative study on domestic bromhexine hydrochloride tablets and primary research preparation》. 《Zhongguo Yaoshi (Beijing, China)》published the findings. The article contains the following contents:

Objective: To evaluate the quality of domestic bromhexine hydrochloride tablets and primary research preparations Methods: The dissolution curves of the tablets and preparation in four dissolution media were compared. The quality of Bromhexine Hydrochloride Tablets was analyzed with the new related substances method. Results: The comparative study showed the dissolution curve of one domestic manufacturer was similar to that of the original manufacturer. Impurity profiles anal. showed that unknown impurity X which came from API was the main reason to influence the purity level of domestic preparations, meanwhile, impurity X was not detected in primary research preparations Conclusion: The quality of API was the main factor to influence the quality of domestic preparations There was difference in manufacturing technique between foreign API and domestic API.2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) were involved in the experimental procedure.

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is a mucolytic agent that exerts both a secretagogic action on submucosal glands and a mucolytic action toward acid glycoproteins inside cells. Bromhexine Hydrochloride is a medication prescribed for coughs which works by dissolving hard phlegm. OthersBromhexine is a mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. In addition, bromhexine has antioxidant properties. COA of Formula: C14H21Br2ClN2

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Rele, Rajan V. published 《Simultaneous UV-spectrophotometric estimation of bromhexine hydrochloride and salbutamol sulphate by first order derivative method in combined dosage form》 in 2015. The article was appeared in 《Journal of Chemical and Pharmaceutical Research》. They have made some progress in their research.HPLC of Formula: 611-75-6 The article mentions the following:

The objective of the study was to develop a simple, accurate, precise and rapid UV spectrophotometric, first order derivative, method for simultaneous estimation of bromhexine hydrochloride and salbutamol sulfate from combined dosage form. The validation was carried out by using ICH guidelines for the determination of bromhexine hydrochloride and salbutamol sulfate by using 0.1N hydrochloric acid as the solvent in pharmaceutical dosage form. The proposed first order derivative method involves the measurement of absorbance of one drug at zero crossing point of other; hence wavelengths 240 nm and 233 nm were selected for the estimation of bromhexine hydrochloride and salbutamol sulfate resp. The linearity of the proposed method was found in the concentration range of 2 to 14 μg /mL (r²= 0.9995) for bromhexine hydrochloride and 2 to 16 μg /mL (r² = 0.9996) for salbutamol sulfate resp. The percentage mean recovery was found to be 100.166 % for bromhexine hydrochloride and 100.147 % for salbutamol sulfate resp. The method was also statistically validated for its linearity, accuracy and precision. Both intra and inter day variations showed less percentage (%) RSD values indicating high grade of precision of this method. And 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) was used in the research process.

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is a mucolytic agent that exerts both a secretagogic action on submucosal glands and a mucolytic action toward acid glycoproteins inside cells. Bromhexine Hydrochloride is a medication prescribed for coughs which works by dissolving hard phlegm. OthersBromhexine is a mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. In addition, bromhexine has antioxidant properties. HPLC of Formula: 611-75-6

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Abdullatif, Hind Ali;Michael, Adel Magdy;Trabik, Yossra Ahmed;Ayad, Miriam Farid published 《Critical assessment of smart calculation-based spectroscopy versus chemometric-assisted methods: application to combined antibiotic formulations》. The research results were published in《European Journal of Chemistry》 in 2022.Category: bromides-buliding-blocks The article conveys some information:

This work describes a comparative study of two multivariate chemometric and univariate spectrophotometric methods for the determination of a ternary drug mixture containing oxytetracycline HCl, bromhexine HCl, and lidocaine HCl. All methods show high sensitivity and similar linearity range. Meanwhile, the chemometric method has the advantage of higher accuracy, higher specificity and better regression parameters. The two spectrophotometric methods are constant multiplication coupled with spectrum subtraction and successive ratio subtraction coupled with spectrum subtraction while the chemometric method used partial least square and principal component regression models. In addition, a spiking technique was used to increase the concentration of bromhexine HCl in the dosage form, allowing its determination despite its low contribution. Methods were successfully applied in the dosage form Oxyclear veterinary injection in pure powder as well as in its pharmaceutical formulation. Statistical comparison showed no significant difference between the developed methods and the reference method. And 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) was used in the research process.

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is a mucolytic agent that exerts both a secretagogic action on submucosal glands and a mucolytic action toward acid glycoproteins inside cells. Bromhexine Hydrochloride is a medication prescribed for coughs which works by dissolving hard phlegm. OthersBromhexine is a mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. In addition, bromhexine has antioxidant properties. Category: bromides-buliding-blocks

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Computed Properties of C14H21Br2ClN2In 2013, Lee, Tae-Woong;Jeong, Rae-Seok;Jeong, Seung-A.;Kim, Jeong-Hyun;Shim, Young-Hun;Kim, In-Kyu;Park, Chang-Won published 《Development of dissolution test method for acebrophylline capsules and bromhexine hydrochloride tablets in Korean pharmaceutical codex》. 《Yakhak Hoechi》published the findings. The article contains the following contents:

Although the dissolution test can serve as an effective tool for quality control and predictor of in vivo performance, there are a number of drugs with no established dissolution specification in Korean Pharmaceutical Codex (KPC). So, with each reference and test drugs, the dissolution test method and an anal. procedure by HPLC were developed and validated to establish dissolution specification for acebrophylline capsules and bromhexine hydrochloride tablets. The dissolution condition was determined based on the “Guidelines on Specifications of Dissolution tests for Oral dosage forms” of Ministry of Food and Drug Safety (MFDS). The anal. method of HPLC was validated in specificity, linearity, precision and accuracy. Final dissolution test was performed with com. available samples of 3 lots to establish specification. In addition, no difference was observed by the inter-laboratory evaluation. Dissolution specifications and conditions will be used for revising the monograph of acebrophylline capsules and bromhexine hydrochloride tablets in next supplement of KPC. To complete the study, the researchers used 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) .

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is intended to support the body’s mechanisms for clearing mucus from the respiratory tract. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.Computed Properties of C14H21Br2ClN2

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Ko, Tai-Ming;Tsai, Chang-Youh;Chen, Shih-Yang;Chen, Kuo-Shu;Yu, Kuang-Hui;Chu, Chih-Sheng;Huang, Chung-Ming;Wang, Chrong-Reen;Weng, Chia-Tse;Yu, Chia-Li;Hsieh, Song-Chou;Tsai, Jer-Chia;Lai, Wen-Ter;Tsai, Wen-Chan;Yin, Guang-Dar;Ou, Tsan-Teng;Cheng, Kai-Hung;Yen, Jeng-Hsien;Liou, Teh-Ling;Lin, Tsung-Hsien;Chen, Der-Yuan;Hsiao, Pi-Jung;Weng, Meng-Yu;Chen, Yi-Ming;Chen, Chen-Hung;Liu, Ming-Fei;Yen, Hsueh-Wei;Lee, Jia-Jung;Kuo, Mei-Chuan;Wu, Chen-Ching;Hung, Shih-Yuan;Luo, Shue-Fen;Yang, Ya-Hui;Chuang, Hui-Ping;Chou, Yi-Chun;Liao, Hung-Ting;Wang, Chia-Wen;Huang, Chun-Lin;Chang, Chia-Shuo;Lee, Ming-Ta Michael;Chen, Pei;Wong, Chih-Shung;Chen, Chien-Hsiun;Wu, Jer-Yuarn;Chen, Yuan-Tsong;Shen, Chen-Yang published 《Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study》 in 2015. The article was appeared in 《BMJ [British Medical Journal]》. They have made some progress in their research.Recommanded Product: 611-75-6 The article mentions the following:

Objective: To evaluate the use of prospective screening for the HLA-B*58:01 allele to identify Taiwanese individuals at risk of severe cutaneous adverse reactions (SCARs) induced by allopurinol treatment. Design: National prospective cohort study. Setting: 15 medical centers in different regions of Taiwan, from July 2009 to August 2014. Participants 2926 people who had an indication for allopurinol treatment but had not taken allopurinol previously. Participants: were excluded if they had undergone a bone marrow transplant, were not of Han Chinese descent, and had a history of allopurinol induced hypersensitivity. DNA purified from 2910 participants’ peripheral blood was used to assess the presence of HLA-B*58:01. Main Outcome Measures: Incidence of allopurinol induced SCARs with and without screening. Results: Participants who tested pos. for HLA-B*58:01 (19.6%, n = 571) were advised to avoid allopurinol, and were referred to an alternate drug treatment or advised to continue with their prestudy treatment. Participants who tested neg. (80.4%, n = 2339) were given allopurinol. Participants were interviewed once a week for two months to monitor symptoms. The historical incidence of allopurinol induced SCARs, estimated by the National Health Insurance research database of Taiwan, was used for comparison. Mild, transient rash without blisters developed in 97 (3%) participants during follow-up. None of the participants was admitted to hospital owing to adverse drug reactions. SCARs did not develop in any of the participants receiving allopurinol who screened neg. for HLA-B*58:01. By contrast, seven cases of SCARs were expected, based on the estimated historical incidence of allopurinol induced SCARs nationwide (0.30% per yr, 95% confidence interval 0.28% to 0.31%; P = 0.0026; two side one sample binomial test). Conclusions: Prospective screening of the HLA-B*58:01 allele, coupled with an alternative drug treatment for carriers, significantly decreased the incidence of allopurinol induced SCARs in Taiwanese medical centers. The experimental procedure involved many compounds, such as 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) .

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is intended to support the body’s mechanisms for clearing mucus from the respiratory tract. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.Recommanded Product: 611-75-6

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Kong, Dexian;Huang, Siqin;Cheng, Jiansong;Zhuang, Qizhao;Liu, Yijun;Lu, Chun-Hua published 《Sensitive determination of bromhexine hydrochloride based on its quenching effect on luminol/H₂O₂ electrochemiluminescence system》 in 2018. The article was appeared in 《Luminescence》. They have made some progress in their research.Quality Control of 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride The article mentions the following:

In this paper, the electrochemiluminescence (ECL) behavior of luminol/H2O2 system in the presence of bromhexine hydrochloride (BrH) was investigated. It was found that the ECL intensity of luminol/H2O2 system on a platinum electrode could be intensely quenched by BrH owing to the scavenging superoxide radical ability of BrH, and therefore the sensitive determination of BrH was possible. Under optimal conditions, the quenched ECL intensity was linear to the concentration of BrH in a wide range of 0.08 to 500μM, with a detection limit of 0.02μM (signal-to-noise ratio (S/N) = 3). This ECL method possessed the merits of rapid, simple and sensitive, and was successfully applied to the BrH quantification in pharmaceutical preparations with satisfactory recoveries of 91.0 ± 4.0 to 106.5 ± 3.4%. The possible route of the quenched ECL of luminol/H2O2 in the presence of BrH was also discussed.2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) were involved in the experimental procedure.

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is intended to support the body’s mechanisms for clearing mucus from the respiratory tract. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.Quality Control of 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Application In Synthesis of 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochlorideIn 2015, Attia, Khalid Abdelsalam M.;Nassar, Mohammed W. I.;Osman, Ayman published 《Different chemometric models applied for the simultaneous determination of certain drugs acting on respiratory system》. 《European Journal of Biomedical and Pharmaceutical Sciences》published the findings. The article contains the following contents:

Different Chemometric models were applied for the quant. anal. of Salbutamol (SL) and bromhexine (BH) in binary mixture, namely, Classical Least Square (CLS), Principle Component Regression (PCR), Artificial Neural Networks (ANN) as advanced model And Genetic algorithm- Artificial Neural Networks GA-ANN. The methods were used for the quant. anal. of the drugs in raw materials and pharmaceutical dosage form via handling the UV spectral data. A 2-factor 5-level exptl. design was established resulting in 25 mixtures containing different ratios of the drugs. Thirteen mixtures were used as a calibration set and the other twelve mixtures were used as validation set to validate the prediction ability of the suggested methods. The experimental procedure involved many compounds, such as 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) .

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is intended to support the body’s mechanisms for clearing mucus from the respiratory tract. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.Application In Synthesis of 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Synthetic Route of C14H21Br2ClN2In 2014, Hildebrand, Marcel;Hamaed, Hiyam;Namespetra, Andrew M.;Donohue, John M.;Fu, Riqiang;Hung, Ivan;Gan, Zhehong;Schurko, Robert W. published 《³⁵Cl solid-state NMR of HCl salts of active pharmaceutical ingredients: structural prediction, spectral fingerprinting and polymorph recognition》. 《CrystEngComm》published the findings. The article contains the following contents:

A series of HCl salts of active pharmaceutical ingredients (APIs) have been characterized via³⁵Cl solid-state NMR (SSNMR) spectroscopy and first-principles plane-wave d. functional theory (DFT) calculations of ³⁵Cl NMR interaction tensors. ³⁵Cl NMR spectra have been acquired at both standard (9.4 T) and high (21.1 T) magnetic field strengths, on stationary samples and under conditions of magic-angle spinning (MAS). The ³⁵Cl elec. field gradient (EFG) and chem. shift (CS) tensor parameters are readily extracted from anal. simulations of these spectra. These parameters are distinct for each sample, indicating that these spectra can be used as fingerprints for identifying unique solid phases. It is possible to correlate the ³⁵Cl EFG parameters (the quadrupolar coupling constant, C_Q, and the asymmetry parameter, η_Q) to the hydrogen-bonding environments of each chlorine anion, and several simple trends are observed ³⁵Cl EFG tensors obtained from plane-wave DFT calculations are found to be in good agreement with experiment, and unique structural insights are gained by considering the predicted EFG tensor orientations and the signs of the quadrupolar coupling constants ³⁵Cl SSNMR can be easily applied for the differentiation of polymorphs of HCl APIs, since the spectra are sensitive to even the subtlest changes in the chlorine anion environments. We discuss the application of this combination of techniques as both standalone and complementary NMR crystallog. methodologies for structural characterization and potential high-throughput screening of polymorphs of HCl APIs. The experimental procedure involved many compounds, such as 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) .

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) is intended to support the body’s mechanisms for clearing mucus from the respiratory tract. Bromhexine is a synthetic derivative of the herbal active ingredient vasicine. It has been shown to increase the proportion of serous bronchial secretion, making it more easily expectorated. It is indicated as secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport.Synthetic Route of C14H21Br2ClN2

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Kajihara, Ryusuke;Noguchi, Shuji;Iwao, Yasunori;Suzuki, Yoshio;Terada, Yasuko;Uesugi, Kentaro;Itai, Shigeru published 《Structural changes of polymer-coated microgranules and excipients on tableting investigated by microtomography using synchrotron X-ray radiation》. The research results were published in《International Journal of Pharmaceutics (Amsterdam, Netherlands)》 in 2015.HPLC of Formula: 611-75-6 The article conveys some information:

Multiple-unit tablets consisting of polymer-coated microgranules and excipients have a number of advantageous pharmaceutical properties. Polymer-coated microgranules are known to often lose their functionality because of damage to the polymer coating caused by tableting, and the mechanism of polymer coating damage as well as the structural changes of excipients upon tableting had been investigated but without in-situ visualization and quant. anal. To elucidate the mechanism of coating damage, the internal structures of multiple-unit tablets were investigated by X-ray computed microtomog. using synchrotron X-rays. Cross sectional images of the tablets with sub-micron spatial resolution clearly revealed that void spaces remained around the compressed excipient particles in the tablets containing an excipient composed of cellulose and lactose (Cellactose 80), whereas much smaller void spaces remained in the tablets containing an excipient made of sorbitol (Parteck SI 150). The relationships between the void spaces and the phys. properties of the tablets such as hardness and disintegration were investigated. Damage to the polymer coating in tablets was found mainly where polymer-coated microgranules were in direct contact with each other in both types of tablets, which could be attributed to the difference in hardness of excipient particles and the core of the polymer-coated microgranules. To complete the study, the researchers used 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) .

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) (BHH; 250μM; 24 hours) also significantly attenuates HGF-induced invasion of LNCaP and C4-2B cells that natively express TMPRSS2. No significant toxicity is observed over a 48-hour period exposing LNCaP, DU145, PC3, or HepG2 cells to Bromhexine hydrochloride concentrations ranging from 0μM to 250μM. Bromhexine hydrochloride exposure does not induce cell death or substantially suppress the growth of DU145 cells.Bromhexine hydrochloride (20 μM; 48 h) inhibits dendritic cells infection with HIV-1.HPLC of Formula: 611-75-6

Reference:
Bromide – Wikipedia,
bromide – Wiktionary

Formula: C14H21Br2ClN2In 2013, Pu, Jiekun;Zhang, Kai;Hao, Xiaofei;Niu, Guizhen;Du, Yumin published 《Synthesis of bromhexine hydrochloride》. 《Zhongguo Yiyao Gongye Zazhi》published the findings. The article contains the following contents:

Bromhexine hydrochloride was synthesized from 2-amino-3,5-dibromobenzaldehyde by reduction with NaBH₄ and chlorination with SOCl₂ to give 2,4-dibromo-6-chloromethylaniline, which was subjected to amination with N-methylcyclohexylamine and salt formation. The overall yield was about 57%. The experimental procedure involved many compounds, such as 2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride (cas: 611-75-6) .

2,4-Dibromo-6-((cyclohexyl(methyl)amino)methyl)aniline hydrochloride(cas: 611-75-6) (BHH; 250μM; 24 hours) also significantly attenuates HGF-induced invasion of LNCaP and C4-2B cells that natively express TMPRSS2. No significant toxicity is observed over a 48-hour period exposing LNCaP, DU145, PC3, or HepG2 cells to Bromhexine hydrochloride concentrations ranging from 0μM to 250μM. Bromhexine hydrochloride exposure does not induce cell death or substantially suppress the growth of DU145 cells.Bromhexine hydrochloride (20 μM; 48 h) inhibits dendritic cells infection with HIV-1.Formula: C14H21Br2ClN2

Reference:
Bromide – Wikipedia,
bromide – Wiktionary